Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) CFO Sells $475,000.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMCGet Free Report) CFO Michael Landsittel sold 5,000 shares of the stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $95.00, for a total value of $475,000.00. Following the sale, the chief financial officer now directly owns 47,286 shares in the company, valued at $4,492,170. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Michael Landsittel also recently made the following trade(s):

  • On Friday, March 15th, Michael Landsittel sold 13,734 shares of Blueprint Medicines stock. The stock was sold at an average price of $87.78, for a total value of $1,205,570.52.
  • On Thursday, March 7th, Michael Landsittel sold 5,003 shares of Blueprint Medicines stock. The stock was sold at an average price of $90.69, for a total value of $453,722.07.

Blueprint Medicines Price Performance

Blueprint Medicines stock opened at $91.56 on Wednesday. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60. The company has a market capitalization of $5.60 billion, a PE ratio of -10.95 and a beta of 0.63. Blueprint Medicines Co. has a 12 month low of $41.54 and a 12 month high of $101.00. The stock has a 50-day moving average price of $87.07 and a two-hundred day moving average price of $74.09.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. The firm had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The business’s quarterly revenue was up 85.5% on a year-over-year basis. During the same period last year, the company earned ($2.65) earnings per share. Analysts expect that Blueprint Medicines Co. will post -5.42 EPS for the current year.

Hedge Funds Weigh In On Blueprint Medicines

Hedge funds have recently made changes to their positions in the stock. Pinebridge Investments L.P. bought a new position in shares of Blueprint Medicines during the second quarter worth about $46,000. Compass Wealth Management LLC bought a new position in shares of Blueprint Medicines during the fourth quarter worth about $69,000. PNC Financial Services Group Inc. raised its position in shares of Blueprint Medicines by 63.4% during the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 329 shares during the last quarter. Van ECK Associates Corp raised its position in shares of Blueprint Medicines by 28.4% during the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 193 shares during the last quarter. Finally, Cutler Group LLC CA raised its position in shares of Blueprint Medicines by 1,685.7% during the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 944 shares during the last quarter.

Analyst Upgrades and Downgrades

BPMC has been the topic of several analyst reports. Wells Fargo & Company increased their target price on Blueprint Medicines from $86.00 to $115.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th. Citigroup raised their price objective on Blueprint Medicines from $54.00 to $65.00 and gave the company a “sell” rating in a research note on Friday, February 16th. Barclays raised their price objective on Blueprint Medicines from $58.00 to $70.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research note on Monday, February 26th. Finally, Stifel Nicolaus raised their price objective on Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Four equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $85.43.

Check Out Our Latest Analysis on Blueprint Medicines

Blueprint Medicines Company Profile

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

See Also

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.